Latest news about Bilcare
Bilcare
94.39
-1.00(-1.05%)
Company Performance:
View Company Insights1D-1.05%
1M+59.25%
6M+48.18%
1Y+48.18%
5Y+48.18%
More news about Bilcare
01Jun 26
Bilcare FY26 net profit at ₹0.99 crore, loss narrows
Bilcare Limited's FY26 standalone net profit fell to ₹0.99 crore from ₹3.99 crore, with revenue dropping to ₹6.85 crore. The consolidated net loss narrowed to ₹17.29 crore. The company redeemed ₹15.60 crore preference shares in Caprihans India Limited and converted warrants, increasing its stake to 62.04%. The auditors flagged a material uncertainty regarding the company's status as a going concern.
23May 26
Bilcare board to meet on May 29 to consider Q4FY26 results
Bilcare Limited will hold a board meeting on May 29, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The trading window is closed until 48 hours post-results declaration.
25Apr 26
Bilcare Limited Announces Director Changes and Board Committee Reconstitution
Bilcare Limited announced the cessation of Mrs. Madhuri Vaidya as Independent Director effective April 26, 2026, upon completion of her second five-year term. The Board appointed Advocate Ashwini Ashok Hasabnis as Non-Executive Independent Woman Director for five years from April 25, 2026, subject to shareholder approval. The company also reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective April 25, 2026.
16Apr 26
Bilcare Limited Files SEBI Compliance Certificate for Quarter Ended March 31, 2026
Bilcare Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, filed through the Bombay Stock Exchange on April 16, 2026. The certificate from registrar MUFG Intime India Private Limited confirms proper processing of dematerialisation requests and adherence to prescribed timelines for securities conversion during the quarter.
31Mar 26
Bilcare Limited Board Meeting Outcome: ₹3.15 Crore Preference Share Redemption
Bilcare Limited announced completion of significant corporate actions following March 30, 2026 board meeting, including redemption of 31.50 lakh preference shares worth ₹3.15 crore from Caprihans India Limited and conversion of 12.90 lakh warrants to equity shares across multiple tranches, increasing its shareholding from 55.99% to 59.56%. The company also completed voluntary liquidation of wholly owned UK subsidiary Bilcare GCS Limited with proceeds of GBP 195,781.83 pending credit to company account.
13Feb 26
Bilcare Limited Reports Mixed Q3FY26 Results with Strong Standalone Performance Offset by Consolidated Losses
Bilcare Limited announced Q3FY26 financial results showing contrasting performance between standalone and consolidated operations. While standalone net profit grew 50.56% to ₹2.71 crores, consolidated operations reported ₹12.81 crores loss despite improvement from previous year. The company also disclosed major corporate actions involving subsidiary Caprihans India Limited including preference share redemption and convertible warrant conversion.
18Aug 25
Bilcare Limited Reports Narrowed Losses in Q1 Amid Challenging Market Conditions
Bilcare Limited's Q1 FY2024 results show a mixed performance. Consolidated total income decreased by 2.75% to ₹192.44 crores, but net loss reduced to ₹9.76 crores from ₹15.02 crores year-over-year. Standalone performance improved with profit after tax more than doubling to ₹3.59 crores. Consolidated EPS improved to ₹(1.59) from ₹(2.71) in the previous year.
21Jul 25
Bilcare Approves Voluntary Liquidation of UK Subsidiary Bilcare GCS
Bilcare Limited's Board of Directors has approved the voluntary liquidation of its wholly-owned UK subsidiary, Bilcare GCS Limited. The decision was made on July 21, 2025. Bilcare GCS contributed only 0.02% to the consolidated turnover with INR 11.88 lacs in FY 2024-25. The liquidation is not expected to significantly impact Bilcare Limited's overall financial position. The process will be carried out in accordance with UK laws, with the completion date yet to be determined.
Industry Peers
Syngene International
Indegene
Suven Life Sciences
Vimta Labs
TAKEBilcare
Jeevan Scientific Technology
Adeshwar Meditex
Vanta Bioscience
406.40
(+1.97%)
563.55
(-0.55%)
360.05
(-2.62%)
626.35
(+1.70%)
18.81
(-4.95%)
94.39
(-1.05%)
75.30
(+1.43%)
16.95
(0.0%)
19.64
(0.0%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
